Pfenex Inc (NYSEAMERICAN:PFNX) was the recipient of a large increase in short interest in the month of December. As of December 29th, there was short interest totalling 198,379 shares, an increase of 13.4% from the December 15th total of 174,975 shares. Currently, 1.0% of the company’s shares are short sold. Based on an average daily trading volume, of 721,971 shares, the short-interest ratio is currently 0.3 days.

PFNX has been the topic of several research analyst reports. JMP Securities reduced their price objective on shares of Pfenex from $21.00 to $8.00 and set an “outperform” rating on the stock in a report on Friday, November 10th. Zacks Investment Research upgraded shares of Pfenex from a “strong sell” rating to a “hold” rating in a report on Wednesday, October 11th. Two analysts have rated the stock with a sell rating and one has assigned a buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus target price of $5.50.

A number of large investors have recently modified their holdings of PFNX. Susquehanna International Group LLP acquired a new position in shares of Pfenex during the second quarter worth about $272,000. Legal & General Group Plc grew its position in shares of Pfenex by 2,567.5% during the second quarter. Legal & General Group Plc now owns 110,249 shares of the biotechnology company’s stock worth $442,000 after buying an additional 106,116 shares in the last quarter. Goldman Sachs Group Inc. grew its position in shares of Pfenex by 186.0% during the second quarter. Goldman Sachs Group Inc. now owns 160,204 shares of the biotechnology company’s stock worth $642,000 after buying an additional 104,184 shares in the last quarter. Dimensional Fund Advisors LP grew its position in shares of Pfenex by 112.1% during the second quarter. Dimensional Fund Advisors LP now owns 201,066 shares of the biotechnology company’s stock worth $806,000 after buying an additional 106,257 shares in the last quarter. Finally, C WorldWide Group Holding A S grew its position in shares of Pfenex by 10.5% during the third quarter. C WorldWide Group Holding A S now owns 271,400 shares of the biotechnology company’s stock worth $820,000 after buying an additional 25,900 shares in the last quarter.

Shares of Pfenex (NYSEAMERICAN:PFNX) opened at $3.45 on Friday. The stock has a market cap of $79.59, a PE ratio of -1.94 and a beta of 3.95. Pfenex has a one year low of $2.07 and a one year high of $9.39.

Pfenex (NYSEAMERICAN:PFNX) last issued its quarterly earnings results on Thursday, November 9th. The biotechnology company reported ($0.37) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.54) by $0.17. The company had revenue of $5.02 million for the quarter, compared to analyst estimates of $3.30 million. Pfenex had a negative net margin of 175.52% and a negative return on equity of 63.57%. The business’s revenue for the quarter was down 89.7% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.46 earnings per share.

TRADEMARK VIOLATION NOTICE: “Short Interest in Pfenex Inc (PFNX) Increases By 13.4%” was originally published by TheOlympiaReport and is owned by of TheOlympiaReport. If you are accessing this news story on another publication, it was illegally stolen and republished in violation of international trademark & copyright law. The correct version of this news story can be read at https://theolympiareport.com/2018/01/13/short-interest-in-pfenex-inc-pfnx-increases-by-13-4.html.

About Pfenex

Pfenex Inc is a clinical-stage biotechnology company. The Company is engaged in the development of biosimilar and therapeutic equivalent products to branded therapeutics and other high-value and difficult-to-manufacture proteins. Its lead product candidate is PF582, a biosimilar candidate to Lucentis (ranibizumab).

Receive News & Ratings for Pfenex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfenex and related companies with MarketBeat.com's FREE daily email newsletter.